As the White House nears a decision on its Section 232 pharmaceutical investigation, which will determine whether imports of pharmaceuticals and their components pose a threat to U.S. national security, that conclusion should already be clear as it relates to generic medicines.

President Trump should treat these more affordable and critical medicines as the national security asset that they are, and build durable public-private partnerships to secure the supply of medicine for Americans for years.

Generics are the backbone of U.S. healthcare, and, like a backbone, we usually don’t notice it until it hurts. Generics fill nine out of 10 prescriptions and lower costs for families, employers and taxpayers to the tune of hundreds of billions of dollars yearly. Too often, we take for granted h

See Full Page